Clinical trial
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
NCT00321633 · University College London Hospitals, Other · Completed
Key facts
| NCT number | NCT00321633 |
|---|---|
| Title | Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer |
| Official title | A Randomized Phase II Pilot Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic Genetic Breast Cancer [BRCA Trial] |
| Lead sponsor | University College London Hospitals, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2) |
| Intervention type | Drug |
| Interventions | carboplatin, docetaxel |
| Enrollment | 148 |
| Start date | Sep 1, 2005 |
| Primary completion | Sep 1, 2009 |
| First posted | May 4, 2006 |
| Last update posted | Aug 26, 2013 |
| Countries | Australia, Israel, Portugal, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: